Loading clinical trials...
Loading clinical trials...
A Phase I/II Trial to Evaluate the Safety, Feasibility and Efficacy of the Addition of Temsirolimus to a Regimen of Bendamustine and Rituximab for the Treatment of Patients With Follicular Lymphoma or Mantle Cell Lymphoma in First to Third Relapse
Conditions
Interventions
Temsirolimus, Rituximab, Bendamustin
Locations
1
Germany
Universitätsmedizin Mainz
Mainz, Rhineland-Palatinate, Germany
Start Date
February 2, 2010
Primary Completion Date
September 8, 2017
Completion Date
September 8, 2017
Last Updated
September 11, 2017
NCT05529069
NCT06263491
NCT06337318
NCT05006716
NCT06026319
NCT07128641
Lead Sponsor
Georg Hess, MD
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions